BioNTech's Trastuzumab Pamirtecan Achieves Phase 3 Success for HER2-Positive Breast Cancer
BioNTech's new "smart bomb" cancer drug, trastuzumab pamirtecan, excelled in trials for HER2+ breast cancer, beating an older therapy. This marks BioNTech's first major oncology success and offers a promising new option for patients, globally.